Recorded Q1’24 consolidated revenue of KRW 946.9 billion Recorded Q1’24 consolidated operating profit of KRW 221.3 billion Sustained growth driven by ongoing strategic expansion in capacity and portfolio INCHEON, South Korea, April 24, 2024 /PRNewswire/ — Samsung Biologics (KRX:…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.